NASDAQ : MCRB
Seres Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 19.59M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 17.78M |
| Enterprise Value | 58.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 10.04M |
| Shares Outstanding | 10.04M |
| Shares Change (YoY) | +10.80% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 9.45% |
| Float | 8.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.44 |
| Forward PS | n/a |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 31.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.11 |
| Quick Ratio | 2.04 |
| Debt / Equity | 1.64 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -66.57% |
| Return on Assets (ROA) | -39.85% |
| Return on Invested Capital (ROIC) | -46.22% |
| Return on Capital Employed (ROCE) | -95.92% |
| Weighted Average Cost of Capital (WACC) | 1.42% |
| Revenue Per Employee | $28,530 |
| Profits Per Employee | -$340,348 |
| Employee Count | 66 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -89.52% |
| 50-Day Moving Average | 3.62 |
| 200-Day Moving Average | 7.11 |
| Relative Strength Index (RSI) | 20.88 |
| Average Volume (20 Days) | 76,796 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 312,339 |
| Short Previous Month | 314,264 |
| Short % of Shares Out | 3.11% |
| Short % of Float | 3.54% |
| Short Ratio (days to cover) | 4.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.88M |
| Gross Profit | -46.08M |
| Operating Income | -78.23M |
| Pretax Income | -22.46M |
| Net Income | -22.46M |
| EBITDA | -74.78M |
| EBIT | -78.23M |
| Loss Per Share | -$2.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 15.59M |
| Total Debt | 56.64M |
| Net Cash | -41.05M |
| Net Cash Per Share | -$4.09 |
| Equity (Book Value) | 34.53M |
| Book Value Per Share | 3.51 |
| Working Capital | 22.32M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -51.26M |
| Capital Expenditures | -37,000 |
| Depreciation & Amortization | 3.45M |
| Net Borrowing | n/a |
| Free Cash Flow | -51.30M |
| FCF Per Share | -$5.11 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -4,154.38% |
| Pretax Margin | -1,192.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.80% |
| Shareholder Yield | -10.80% |
| Earnings Yield | -136.29% |
| FCF Yield | -288.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.00 |
| Price Target Difference | 860.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -23.16% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -14.8 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |